Genetic Technologies Limited
GNTLF
$0.00
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -19.33% | -21.32% | -5.56% |
| Total Other Revenue | -54.72% | -53.67% | 28.81% | 25.60% | 9.97% |
| Total Revenue | -54.72% | -53.67% | -11.83% | -14.00% | -81.80% |
| Cost of Revenue | -- | -- | -9.62% | -11.86% | -- |
| Gross Profit | -54.72% | -53.67% | -13.33% | -15.47% | -67.99% |
| SG&A Expenses | -32.26% | -30.68% | 10.98% | 8.24% | -67.87% |
| Depreciation & Amortization | -58.53% | -57.59% | -27.57% | -29.39% | -53.59% |
| Other Operating Expenses | -54.61% | -53.56% | -10.99% | -13.18% | -35.57% |
| Total Operating Expenses | -41.88% | -40.53% | -2.91% | -5.31% | -70.25% |
| Operating Income | 36.55% | 35.06% | -6.61% | -3.98% | 59.58% |
| Income Before Tax | -43.95% | -47.31% | 12.35% | 14.52% | 62.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.95% | -47.31% | 12.21% | 14.38% | 61.51% |
| Earnings from Discontinued Operations | 75.96% | 75.39% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.34% | 34.86% | 12.21% | 14.38% | -16.50% |
| EBIT | 36.55% | 35.06% | -6.61% | -3.98% | 59.58% |
| EBITDA | 34.88% | 33.36% | -2.65% | -0.11% | 59.97% |
| EPS Basic | 49.17% | 47.80% | 34.74% | 36.41% | 6.70% |
| Normalized Basic EPS | 45.95% | 44.74% | 14.44% | 16.30% | 68.91% |
| EPS Diluted | 49.17% | 47.80% | 34.74% | 36.41% | 6.70% |
| Normalized Diluted EPS | 45.95% | 44.74% | 14.44% | 16.30% | 68.91% |
| Average Basic Shares Outstanding | 25.00% | 25.00% | 34.95% | 34.95% | 24.99% |
| Average Diluted Shares Outstanding | 25.00% | 25.00% | 34.95% | 34.95% | 24.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |